Maryse Larouche1,2, Arianne Y K Albert3, Nancy Lipsky3, Sharon Walmsley4, Mona Loutfy5, Fiona Smaill6, Sylvie Trottier7, Ari Bitnun8, Mark H Yudin9, Geoffrey W Cundiff10, Deborah M Money3,10. 1. Department of Obstetrics and Gynecology, McGill University, Montreal, QC, Canada. ml.larouche@mcgill.ca. 2. St. Mary's Research Centre, St. Mary's Hospital, Hayes Pavilion, room 4729, 3830 Lacombe, Montreal, Quebec, H3T 1M5, Canada. ml.larouche@mcgill.ca. 3. Women's Health Research Institute, Vancouver, BC, Canada. 4. Department of Infectious Diseases, Toronto General Hospital, Toronto, ON, Canada. 5. Department of Infectious Diseases, Women's College Hospital, Toronto, ON, Canada. 6. Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada. 7. Department of Microbiology, Infectious Diseases and Immunology, CHUQ/CHUL, Quebec, QC, Canada. 8. Department of Infectious Diseases, SickKids, Toronto, ON, Canada. 9. Department of Obstetrics and Gynecology & Reproductive Infectious Diseases, St. Michael's Hospital, Toronto, ON, Canada. 10. Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.
Abstract
INTRODUCTION AND HYPOTHESIS: To determine prevalence and quality of life impact of lower urinary tract symptoms (LUTS) in women living with HIV (WLWH). METHODS: Cross-sectional urinary questionnaires were included in a multicenter national prospective study of the HPV vaccine in WLWH. Demographic and clinical information was abstracted from the parent study. The Urinary Distress Inventory (UDI-6) and Urinary Impact Questionnaire (UIQ-7) were administered. Wilcoxon rank sum, two-sample chi-square or Fisher's exact tests were used as appropriate to compare women with UDI-6 score ≥ 25 to those with lower UDI-6 scores on demographic and HIV-related factors. Significant categorical variables were followed up with logistic regression to estimate odds ratios (OR). RESULTS: One hundred seventy-seven women completed urinary questionnaires (85.5% of cohort). Median age was 44.1 (37.2-50.6). Mean CD4 count was 621 (410-785), and 132 women (74.6%) were virologically suppressed. Median UDI-6 score was 4.2 (0-25). Fifty-one women (28.8%) had a UIQ-7 score > 0. Among those with a UDI-6 score of at least 25, median UIQ-7 was 9.5 (0-47.6). UDI-6 ≥ 25 was significantly associated with increasing age, higher BMI, Canada as country of origin, peri-/postmenopausal status (OR 3.37, 95% CI = 1.71 to 6.75) and being parous (OR 2.92, 95% CI = 1.27 to 7.59) (all p < 0.05). HIV-related factors were not associated with UDI-6 ≥ 25. CONCLUSIONS: LUTS were common, but we did not demonstrate a negative impact on quality of life in this sample of WLWH. Large comparative studies are needed to determine whether HIV is a risk factor for bothersome LUTS in women.
INTRODUCTION AND HYPOTHESIS: To determine prevalence and quality of life impact of lower urinary tract symptoms (LUTS) in women living with HIV (WLWH). METHODS: Cross-sectional urinary questionnaires were included in a multicenter national prospective study of the HPV vaccine in WLWH. Demographic and clinical information was abstracted from the parent study. The Urinary Distress Inventory (UDI-6) and Urinary Impact Questionnaire (UIQ-7) were administered. Wilcoxon rank sum, two-sample chi-square or Fisher's exact tests were used as appropriate to compare women with UDI-6 score ≥ 25 to those with lower UDI-6 scores on demographic and HIV-related factors. Significant categorical variables were followed up with logistic regression to estimate odds ratios (OR). RESULTS: One hundred seventy-seven women completed urinary questionnaires (85.5% of cohort). Median age was 44.1 (37.2-50.6). Mean CD4 count was 621 (410-785), and 132 women (74.6%) were virologically suppressed. Median UDI-6 score was 4.2 (0-25). Fifty-one women (28.8%) had a UIQ-7 score > 0. Among those with a UDI-6 score of at least 25, median UIQ-7 was 9.5 (0-47.6). UDI-6 ≥ 25 was significantly associated with increasing age, higher BMI, Canada as country of origin, peri-/postmenopausal status (OR 3.37, 95% CI = 1.71 to 6.75) and being parous (OR 2.92, 95% CI = 1.27 to 7.59) (all p < 0.05). HIV-related factors were not associated with UDI-6 ≥ 25. CONCLUSIONS: LUTS were common, but we did not demonstrate a negative impact on quality of life in this sample of WLWH. Large comparative studies are needed to determine whether HIV is a risk factor for bothersome LUTS in women.
Entities:
Keywords:
HIV; Lower urinary tract symptoms (LUTS); Urinary incontinence; Women living with HIV
Authors: J B Kopp; K D Miller; J A Mican; I M Feuerstein; E Vaughan; C Baker; L K Pannell; J Falloon Journal: Ann Intern Med Date: 1997-07-15 Impact factor: 25.391
Authors: Karin S Coyne; Chris C Sexton; Christine L Thompson; Ian Milsom; Debra Irwin; Zoe S Kopp; Christopher R Chapple; Steven Kaplan; Andrea Tubaro; Lalitha P Aiyer; Alan J Wein Journal: BJU Int Date: 2009-03-05 Impact factor: 5.588
Authors: Karin S Coyne; Alan J Wein; Andrea Tubaro; Chris C Sexton; Christine L Thompson; Zoe S Kopp; Lalitha P Aiyer Journal: BJU Int Date: 2009-04 Impact factor: 5.588